AbbVie Reports Second-Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
BMO Capital Keeps AbbVie (ABBV) at 'Market Perform'; Says Humira Solid in Q2, but Questions Remain
July 29, 2016 11:54 AM EDTBMO Capital affirms AbbVie (NYSE: ABBV) at Market Perform with a price target of $66 following Q2 results out earlier Friday.
Analyst Alex Arfaei commented, revenue was 3.7% above consensus, driven by higher sales of Humira and Imbruvica, while OPEX was... More



